Rejeunesse Fine — UPHEC HA Filler for Superficial Wrinkles & Fine Lines

Rejeunesse Fine is Newmedic’s lightest variant — 24 mg/mL cross-linked HA + 0.3% lidocaine via patented UPHEC (Ultra-Purified High-Efficiency Cross-linking) purification process. Endotoxin levels below 1.2 EU/mL with no residual BDDE detected. Engineered for superficial-to-mid dermal placement targeting fine wrinkles, periorbital area, and lip contour refinement.

Rejeunesse Fine with Lidocaine is manufactured by Newmedic Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2014. The product is part of the Rejeunesse dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE marked · GMP certified.

Rejeunesse Fine with Lidocaine contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Newmedic Co. Ltd.’s UPHEC (Ultra-Purified High-Efficiency Cross-linking) Technology technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Newmedic Co. Ltd.’s clinical data, Rejeunesse Fine with Lidocaine delivers 8-12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Superficial to mid dermis placement typically delivers the longer end of the duration range.

Rejeunesse Fine with Lidocaine is engineered for superficial to mid dermis placement. The standard recommended needle is 30G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Rejeunesse Fine with Lidocaine regulatory status: KFDA registered · CE marked · GMP certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Rejeunesse Fine with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Rejeunesse Fine with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Rejeunesse Fine with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

UPHEC (Ultra-Purified High-Efficiency Cross-linking) is Newmedic’s proprietary 8-stage purification process used across the Rejeunesse range. The technology removes endotoxins and impurities from the HA matrix with sufficient thoroughness to keep final endotoxin levels below 1.2 EU/mL and ensure no detectable BDDE residue. Combined with HCCL (High Concentration Cross-Linking), UPHEC produces a gel exceeding both European and Japanese Pharmacopoeia purity standards — supporting reduced post-injection inflammation risk and sustained durability.